AAgilent Technologies
Price
+34%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, no red flags, price roughly fair, growing in the filings, the market undecided.
Our Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide specialty contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level.
In the company’s own words · 10-K filed Dec 22, 2025 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Agilent Technologies (A) reported revenue of $1.88B in Q3 2026 (quarter ended Jul 31, 2026), up 8.1% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $362M (19% of revenue). For the full year FY2025, revenue was $6.95B (+6.7% year on year) and net income $1.30B. Its largest segment in Q2 2026 (quarter ended Apr 30, 2026) was Life Sciences And Diagnostics Markets at $363M, 48% of the disclosed total, ahead of Agilent Cross Lab at 38%. The next results filing is expected around Nov 23, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026On September 2, 2026, Boon Hwee Koh, Chairperson of the Board of Directors (the "Board") of Agilent Technologies, Inc. (the "Company"), notified the Company of his decision to retire from the Board, effective as of September 4, 2026.Director or officer change · Form 8-K
- Aug 26, 2026Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results.Earnings release · press release
- Jun 25, 2026On June 25, 2026, Agilent Technologies, Inc. (the “Company”) closed the sale of $600 million in aggregate principal amount of its 4.900% Senior Notes due 2032 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $764.0MThe company’s own SEC segment disclosure.
- Life Sciences And Diagnostics Markets$363.0M48%
- Agilent Cross Lab$289.0M38%
- Applied Markets$112.0M15%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry